Peptidylarginine deiminase 4 (PAD4) activity in early rheumatoid arthritis.

Conclusion: Serum capacity to activate PAD4 was associated with ACPA and RF positivity and earlier disease onset in early RA patients, and decreased after initiation of DMARD treatment, indicating that anti-PAD treatment could potentially be beneficial in RA. PMID: 31544586 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31544586?dopt=Abstract

Source: Scandinavian Journal of Rheumatology - September 22, 2019 Category: Rheumatology Authors: Jonsson MK, Kantyka T, Falkowski K, Aliko A, Aga AB, Lillegraven S, Sexton J, Fevang BT, Mydel P, Haavardsholm EA Tags: Scand J Rheumatol Source Type: research